0.76
price down icon1.53%   -0.0118
after-market Handel nachbörslich: .76
loading
Schlusskurs vom Vortag:
$0.7718
Offen:
$0.8
24-Stunden-Volumen:
99,503
Relative Volume:
0.39
Marktkapitalisierung:
$57.78M
Einnahmen:
$1.29M
Nettoeinkommen (Verlust:
$-29.87M
KGV:
-2.1111
EPS:
-0.36
Netto-Cashflow:
$-14.70M
1W Leistung:
+13.23%
1M Leistung:
+47.43%
6M Leistung:
+17.28%
1J Leistung:
+14.27%
1-Tages-Spanne:
Value
$0.7214
$0.80
1-Wochen-Bereich:
Value
$0.66
$0.94
52-Wochen-Spanne:
Value
$0.3951
$0.94

VolitionRX Ltd Stock (VNRX) Company Profile

Name
Firmenname
VolitionRX Ltd
Name
Telefon
646 650 1351
Name
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Name
Mitarbeiter
37
Name
Twitter
@VolitionRx
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
VNRX's Discussions on Twitter

Vergleichen Sie VNRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
VNRX
VolitionRX Ltd
0.76 57.78M 1.29M -29.87M -14.70M -0.36
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
410.65 156.49B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
201.00 145.01B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
530.40 42.30B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
118.62 34.24B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
158.71 27.64B 15.50B 1.33B 2.16B 7.34

VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet H.C. Wainwright Buy
2023-02-01 Herabstufung The Benchmark Company Buy → Hold
2022-02-17 Fortgesetzt Cantor Fitzgerald Overweight
2021-03-10 Eingeleitet Cantor Fitzgerald Overweight
2018-05-16 Eingeleitet Maxim Group Buy
2018-05-14 Bestätigt The Benchmark Company Buy
2016-09-07 Bestätigt Rodman & Renshaw Buy
2016-02-01 Eingeleitet Rodman & Renshaw Buy
Alle ansehen

VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten

pulisher
Jun 16, 2025

VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock By Investing.com - Investing.com India

Jun 16, 2025
pulisher
Jun 16, 2025

VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock - Investing.com

Jun 16, 2025
pulisher
Jun 12, 2025

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure - MarketScreener

Jun 12, 2025
pulisher
Jun 11, 2025

VolitionRx (NYSE:VNRX) Rating Increased to Strong-Buy at Jones Trading - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

VolitionRX (VNRX) Coverage Initiated with a 'Buy' Rating by Jones Trading | VNRX Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

JonesTrading Initiates Coverage on VolitionRx Limited With Buy Rating, $3 Price Target - marketscreener.com

Jun 10, 2025
pulisher
Jun 09, 2025

Jones Trading initiates VolitionRX with Buy, sets $3 target By Investing.com - Investing.com India

Jun 09, 2025
pulisher
Jun 09, 2025

VolitionRx (VNRX) Receives Buy Rating with Promising Price Targe - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

VolitionRx initiated with a Buy at JonesResearch - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

VolitionRx (VNRX) Receives Buy Rating with Promising Price Target | VNRX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 04, 2025

Director Makes Bold Move with Major VolitionRX Stock Purchase - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

VolitionRx director Guy Innes buys $10,772 in common stock By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

VolitionRx director Guy Innes buys $10,772 in common stock - Investing.com

Jun 04, 2025
pulisher
May 27, 2025

VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree

May 27, 2025
pulisher
May 27, 2025

VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance

May 27, 2025
pulisher
May 20, 2025

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 20, 2025
pulisher
May 19, 2025

VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks

May 19, 2025
pulisher
May 19, 2025

VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada

May 19, 2025
pulisher
May 19, 2025

VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India

May 19, 2025
pulisher
May 19, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada

May 19, 2025
pulisher
May 17, 2025

VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

VolitionRx Reports Strong Q1 2025 Performance - TipRanks

May 17, 2025
pulisher
May 16, 2025

VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com

May 16, 2025
pulisher
May 16, 2025

Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK

May 16, 2025
pulisher
May 16, 2025

VolitionRX: Q1 Earnings Snapshot - CT Insider

May 16, 2025
pulisher
May 16, 2025

VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat

May 16, 2025
pulisher
May 15, 2025

Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks

May 15, 2025
pulisher
May 15, 2025

Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus

May 15, 2025
pulisher
May 15, 2025

VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus

May 15, 2025
pulisher
May 12, 2025

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance

May 12, 2025
pulisher
May 10, 2025

VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com

May 09, 2025
pulisher
May 07, 2025

VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World

May 07, 2025
pulisher
Apr 29, 2025

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - Yahoo Finance

Apr 29, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 23, 2025

VolitionRx enters new sales agreement, terminates old one - Investing.com Australia

Apr 23, 2025
pulisher
Apr 22, 2025

VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa

Apr 22, 2025

Finanzdaten der VolitionRX Ltd-Aktie (VNRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

VolitionRX Ltd-Aktie (VNRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Innes Guy Archibald
Director
Jun 03 '25
Buy
0.54
20,000
10,772
888,689
Micallef Jacob Vincent
Chief Scientific Officer
May 19 '25
Buy
0.43
50,000
21,500
426,033
Reynolds Cameron John
President and CEO
May 19 '25
Buy
0.44
20,000
8,730
2,319,222
Reynolds Cameron John
President and CEO
Mar 26 '25
Buy
0.55
181,818
100,000
2,299,222
Innes Guy Archibald
Director
Mar 26 '25
Buy
0.55
181,818
100,000
868,689
Innes Guy Archibald
Director
Dec 09 '24
Buy
0.57
174,764
100,000
617,085
STILL TIMOTHY I
Director
Dec 09 '24
Buy
0.57
87,382
50,000
1,487,382
Micallef Jacob Vincent
Chief Scientific Officer
Dec 09 '24
Buy
0.57
43,691
25,000
394,352
Reynolds Cameron John
President and CEO
Dec 09 '24
Buy
0.57
139,811
80,000
2,117,404
Innes Guy Archibald
Director
Aug 20 '24
Buy
0.67
150,000
100,500
406,683
diagnostics_research DGX
$178.65
price down icon 0.69%
diagnostics_research WAT
$350.01
price up icon 0.93%
diagnostics_research LH
$258.70
price down icon 1.46%
$164.16
price down icon 4.49%
diagnostics_research MTD
$1,192.85
price up icon 0.65%
diagnostics_research IQV
$158.71
price up icon 0.08%
Kapitalisierung:     |  Volumen (24h):